HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

HHS told the Sec­ond Cir­cuit that Boehringer In­gel­heim’s vol­un­tary par­tic­i­pa­tion in Medicare ne­go­ti­a­tions “un­der­mines” its le­gal chal­lenge to the process.

Vol­un­tari­ness was a key fac­tor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER